Methanolic Extract of Boswellia serrata Gum Protects the Nigral Dopaminergic Neurons from Rotenone-Induced Neurotoxicity.
AMP-Activated Protein Kinases
/ metabolism
Animals
Boswellia
/ metabolism
Dopamine
/ metabolism
Dopaminergic Neurons
/ metabolism
Mammals
/ metabolism
Methanol
/ metabolism
Mice
Neuroprotective Agents
/ metabolism
Neurotoxicity Syndromes
/ metabolism
Plant Extracts
/ metabolism
Rotenone
/ pharmacology
alpha-Synuclein
/ metabolism
Boswellia serrata
Locomotor
Mice
Neurodegenerative disease
Parkinson’s disease
Rotenone
Journal
Molecular neurobiology
ISSN: 1559-1182
Titre abrégé: Mol Neurobiol
Pays: United States
ID NLM: 8900963
Informations de publication
Date de publication:
Sep 2022
Sep 2022
Historique:
received:
19
01
2022
accepted:
28
06
2022
pubmed:
9
7
2022
medline:
25
8
2022
entrez:
8
7
2022
Statut:
ppublish
Résumé
Boswellia serrata gum is a natural product that showed beneficial effects on neurodegenerative diseases in recent studies. In this study, we investigated the effects of Boswellia serrata resin on rotenone-induced dopaminergic neurotoxicity. Firstly, we attempted to see if the resin can induce AMP-activated protein kinase (AMPK) signaling pathway which has been known to have broad neuroprotective effects. Boswellia increased AMPK phosphorylation and reduced phosphorylation of mammalian target of rapamycin (p-mTOR) and α-synuclein (p-α-synuclein) in the striatum while increased the expression level of Beclin1, a marker for autophagy and brain-derived neurotrophic factor. Next, we examined the neuroprotective effects of the Boswellia extract in the rotenone-injected mice. The results showed that Boswellia evidently attenuated the loss of the nigrostriatal dopaminergic neurons and microglial activation caused by rotenone. Moreover, Boswellia ameliorated rotenone-induced decrease in the striatal dopamine and impairment in motor function. Accumulation of α-synuclein meditated by rotenone was significantly ameliorated by Boswellia. Also, we showed that β-boswellic acid, the active constituents of Boswellia serrata gum, induced AMPK phosphorylation and attenuated α-synuclein phosphorylation in SHSY5 cells. These results suggest that Boswellia protected the dopaminergic neurons from rotenone neurotoxicity via activation of the AMPK pathway which might be associated with attenuation of α-synuclein aggregation and neuroinflammation. Further investigations are warranted to identify specific molecules in Boswellia which are responsible for the neuroprotection.
Identifiants
pubmed: 35804280
doi: 10.1007/s12035-022-02943-y
pii: 10.1007/s12035-022-02943-y
pmc: PMC9395310
doi:
Substances chimiques
Neuroprotective Agents
0
Plant Extracts
0
alpha-Synuclein
0
Rotenone
03L9OT429T
AMP-Activated Protein Kinases
EC 2.7.11.31
Dopamine
VTD58H1Z2X
Methanol
Y4S76JWI15
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
5874-5890Subventions
Organisme : Yeungnam University
ID : 2020
Informations de copyright
© 2022. The Author(s).
Références
Cell Mol Life Sci. 2000 Dec;57(13-14):1894-908
pubmed: 11215516
Nature. 1991 Mar 21;350(6315):230-2
pubmed: 2005978
Nat Med. 2009 Mar;15(3):331-7
pubmed: 19198615
Curr Opin Neurol. 2002 Aug;15(4):467-76
pubmed: 12151845
Mol Cell. 2008 Apr 25;30(2):214-26
pubmed: 18439900
Front Cell Dev Biol. 2019 Aug 22;7:170
pubmed: 31508418
Drugs Aging. 2011 Aug 1;28(8):605-15
pubmed: 21812497
Cell Death Dis. 2018 Jul 26;9(8):818
pubmed: 30050065
Ann Neurol. 2008 Jun;63(6):743-50
pubmed: 18571778
Oncogene. 2013 May 2;32(18):2261-72, 2272e.1-11
pubmed: 22733132
Science. 1997 Jun 27;276(5321):2045-7
pubmed: 9197268
Biochem Pharmacol. 2020 Oct;180:114193
pubmed: 32800853
Nat Cell Biol. 2002 Feb;4(2):160-4
pubmed: 11813001
Can J Physiol Pharmacol. 2017 Jul;95(7):819-829
pubmed: 28249117
Indian J Pharm Sci. 2011 May;73(3):255-61
pubmed: 22457547
PLoS One. 2010 Feb 19;5(2):e9313
pubmed: 20174468
J Control Release. 2022 May;345:147-175
pubmed: 35248646
Mol Neurobiol. 2018 Jan;55(1):554-566
pubmed: 27975170
Nat Cell Biol. 2011 Feb;13(2):132-41
pubmed: 21258367
J Neurol Neurosurg Psychiatry. 1988 Jun;51(6):745-52
pubmed: 2841426
Nat Genet. 1998 Feb;18(2):106-8
pubmed: 9462735
Nature. 1997 Aug 28;388(6645):839-40
pubmed: 9278044
Sci Rep. 2016 Sep 29;6:33146
pubmed: 27680387
J Biochem Mol Toxicol. 2020 Dec;34(12):e22605
pubmed: 32830361
Cell Res. 2010 Mar;20(3):314-31
pubmed: 19935772
Nat Methods. 2012 Jun 28;9(7):676-82
pubmed: 22743772
BMJ. 2008 Dec 17;337:a2813
pubmed: 19091760
Proc Natl Acad Sci U S A. 2006 Feb 7;103(6):1661-8
pubmed: 16449387
Oncol Rep. 2018 Jan;39(1):129-137
pubmed: 29115548
Curr Opin Neurol. 2012 Aug;25(4):433-47
pubmed: 22691758
Int J Mol Sci. 2022 Feb 24;23(5):
pubmed: 35269632
Neurol Sci. 2010 Jun;31(3):315-20
pubmed: 20217445
J Clin Invest. 2009 Nov;119(11):3257-65
pubmed: 19855133
Cell. 2003 Nov 26;115(5):577-90
pubmed: 14651849
Nat Rev Drug Discov. 2006 Oct;5(10):845-54
pubmed: 17016425
Exp Neurol. 2003 Jan;179(1):9-16
pubmed: 12504863
Turk J Med Sci. 2016 Nov 17;46(5):1573-1578
pubmed: 27966331
J Tradit Complement Med. 2013 Oct;3(4):221-6
pubmed: 24716181
Neurochem Int. 2017 Jan;102:79-88
pubmed: 27956238
Phytomedicine. 2003 Jan;10(1):3-7
pubmed: 12622457
Proc Natl Acad Sci U S A. 2013 May 7;110(19):E1817-26
pubmed: 23610405
Exp Neurobiol. 2020 Jun 30;29(3):207-218
pubmed: 32624505
Neuropathology. 2007 Oct;27(5):494-506
pubmed: 18018486
J Pharm Pharmacol. 2009 Oct;61(10):1281-93
pubmed: 19814859
J Neurol Neurosurg Psychiatry. 2005 Nov;76(11):1472-8
pubmed: 16227533
Neurosci Lett. 1999 Jul 23;270(1):45-8
pubmed: 10454142
Brain Res Mol Brain Res. 1999 Mar 20;66(1-2):62-70
pubmed: 10095078
J Neurosci. 1995 Dec;15(12):7810-20
pubmed: 8613721
Acta Neuropathol Commun. 2014 Dec 13;2:176
pubmed: 25497491
J Biol Chem. 2003 Jul 4;278(27):25009-13
pubmed: 12719433
Neurobiol Dis. 2021 Dec;161:105560
pubmed: 34767944
Mol Neurodegener. 2017 Nov 3;12(1):80
pubmed: 29100525
Neuropharmacology. 2017 Oct;125:396-407
pubmed: 28807678
Am J Physiol Gastrointest Liver Physiol. 2006 Jun;290(6):G1131-7
pubmed: 16423918
Mov Disord. 1999 Jan;14(1):6-9
pubmed: 9918338
Nat Neurosci. 2000 Dec;3(12):1301-6
pubmed: 11100151
Front Pharmacol. 2014 Jan 10;4:177
pubmed: 24454289
Mov Disord. 2002;17 Suppl 3:S28-40
pubmed: 11948753